Acute and long-term treatment and prevention of relapse of obsessive-compulsive disorder with paroxetine

Journal of Clinical Psychiatry

Volumn 64, Issue 9, 2003, Pages 1113-1121

  Hollander, Eric ^a   Allen, Andrea ^a   Steiner, Martin ^b   Wheadon, David E ^b   Oakes, Rosemary ^b   Burnham, Daniel B ^b  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORAL HYDRATE; CLOMIPRAMINE; FLUOXETINE; PAROXETINE; PLACEBO; SEROTONIN UPTAKE INHIBITOR;

ADOLESCENT; ADULT; AGED; ANOREXIA; ANXIETY DISORDER; ARTICLE; ASTHENIA; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DIARRHEA; DISEASE DURATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EJACULATION DISORDER; FEMALE; FOLLOW UP; GENERAL CONDITION IMPROVEMENT; HEADACHE; HUMAN; IMPOTENCE; INFECTION; INSOMNIA; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; NAUSEA; NERVOUSNESS; NEUROSIS; OBSESSIVE COMPULSIVE DISORDER; OPEN STUDY; PARESTHESIA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROPHYLAXIS; PSYCHOPHARMACOTHERAPY; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; RELAPSE; RESPIRATORY TRACT DISEASE; SCORING SYSTEM; SHORT COURSE THERAPY; SIDE EFFECT; SOMNOLENCE; STATISTICAL SIGNIFICANCE; TINNITUS; TREATMENT OUTCOME; TREMOR; UNPLEASANT DREAM; VERTIGO; WEIGHT GAIN; XEROSTOMIA;

EID: 0141493856     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v64n0919     Document Type: Article

References (37)

1. Goodman WK, Price LH, Delgado PL, et al. Specificity of serotonin reuptake inhibitors in the treatment of obsessive-compulsive disorder: comparison of fluvoxamine and desipramine. Arch Gen Psychiatry 1990;47:577-585
2. Jenike MA, Hyman S, Baer L, et al. A controlled trial of fluvoxamine in obsessive-compulsive disorder: implications for a serotonergic theory. Am J Psychiatry 1990;147:1209-1215
3. The Clomipramine Collaborative Study Group. Clomipramine in the treatment of patients with obsessive-compulsive disorder. Arch Gen Psychiatry 1991;48:730-738
4. Tollefson GD, Rampey AH Jr, Potvin JH, et al. A multicenter investigation of fixed-dose fluoxetine in the treatment of obsessive-compulsive disorder. Arch Gen Psychiatry 1994;51:559-567
5. Greist JH, Chouinard G, DuBoff E, et al. Double-blind parallel comparison of three dosages of sertraline and placebo in outpatients with obsessive-compulsive disorder. Arch Gen Psychiatry 1995;52:289-295
6. Greist JH, Jefferson JW, Kobak KA, et al. Efficacy and tolerability of serotonin transport inhibitors in obsessive-compulsive disorder: a meta-analysis. Arch Gen Psychiatry 1995;52:53-60
7. Goodman WK, Kozak MJ, Liebowitz M, et al. Treatment of obsessive-compulsive disorder with fluvoxamine: a multicentre, double-blind, placebo-controlled trial. Int Clin Psychopharmacol 1996;11:21-29
8. Jenike MA, Baer L, Minichiello WE, et al. Placebo-controlled trial of fluoxetine and phenelzine for obsessive-compulsive disorder. Am J Psychiatry 1997;154:1261-1264
9. March JS, Biederman J, Wolkow R, et al. Sertraline in children and adolescents with obsessive-compulsive disorder: a multicenter randomized controlled trial. JAMA 1998;280:1752-1756
10. Riddle MA, Scahill L, King RA, et al. Double-blind, crossover trial of fluoxetine and placebo in children and adolescents with obsessive-compulsive disorder. J Am Acad Child Adolesc Psychiatry 1992;31:1062-1069
11. Montgomery SA, Kasper S, Stein DJ, et al. Citalopram 20 mg, 40 mg, and 60 mg are all effective and well tolerated compared with placebo in obsessive-compulsive disorder. Int Clin Psychopharmacol 2001;16:75-86
12. Ackerman DL, Greenland S, Bystritsky A. Clinical characteristics of response to fluoxetine treatment of obsessive-compulsive disorder. J Clin Psychopharmacol 1998;3:185-192
13. Pato MT, Zohar-Kadouch R, Zohar J, et al. Return of symptoms after discontinuation of clomipramine in patients with obsessive-compulsive disorder. Am J Psychiatry 1988;145:1521-1525
14. Leonard HL, Swedo SE, Lenane MC, et al. A double-blind desipramine substitution during long-term clomipramine treatment in children and adolescents with obsessive-compulsive disorder. Arch Gen Psychiatry 1991;48:922-927
15. Koran LM, Hackett E, Rubin A, et al. Efficacy of sertraline in the long-term treatment of obsessive compulsive disorder. Am J Psychiatry 2002;159:88-95
16. Orloff LM, Battle MA, Baer L, et al. Long-term follow-up of 85 patients with obsessive-compulsive disorder. Am J Psychiatry 1994;151:441-442
17. Rasmussen S, Hackett E, DuBoff E, et al. A 2-year study of sertraline in the treatment of obsessive-compulsive disorder. Int Clin Psychopharmacol 1997;6:309-316
18. Greist JH, Jefferson JW, Kobak KA, et al. A 1 year double-blind placebo-controlled fixed dose study of sertraline in the treatment of obsessive-compulsive disorder. Int Clin Psychopharmacol 1995;10:57-65
19. Tollefson GD, Birkett M, Koran L, et al. Continuation treatment of OCD: double-blind and open-label experience with fluoxetine. J Clin Psychiatry 1994;55(suppl 10):69-76; discussion 77-78
20. Ravizza L, Barzega G, Bellino S, et al. Drug treatment of obsessive-compulsive disorder (OCD): long-term trial with clomipramine and selective serotonin reuptake inhibitors (SSRIs). Psychopharmacol Bull 1996;32:167-173
21. Nemeroff CB. Paroxetine: an overview of the efficacy and safety of a new SSRI in the treatment of depression. J Clin Psychopharmacol 1993; 13(suppl):10S-17S
22. Ballenger JC, Wheadon DE, Steiner M, et al. Double-blind, fixed-dose, placebo-controlled study of paroxetine in the treatment of panic disorder. Am J Psychiatry 1998;155:36-42
23. Stein MB, Liebowitz MR, Lydiard RB, et al. Paroxetine treatment of generalized social phobia (social anxiety disorder): a randomized controlled trial. JAMA 1998;280:708-713
24. Zohar J, Judge R. Paroxetine versus clomipramine in the treatment of obsessive-compulsive disorder. OCD Paroxetine Study Investigators. Br J Psychiatry 1996;169:468-474
25. Insel TR, Murphy DL, Cohen RM, et al. Obsessive-compulsive disorder: a double-blind trial of clomipramine and clorgyline. Arch Gen Psychiatry 1983;40:605-612
26. Goodman WK, Price LH, Rasmussen SA, et al. Yale-Brown Obsessive-Compulsive Scale, 2: validity. Arch Gen Psychiatry 1989;46:1012-1016
27. Goodman WK, Price LH, Rasmussen SA, et al. The Yale-Brown Obsessive-Compulsive Scale, 1: development, use and reliability. Arch Gen Psychiatry 1989;46:1006-1011
28. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62
29. Guy W. ECDEU Assessment Manual for Psychopharmacology. US Dept Health, Education, and Welfare publication (ADM) 76-338. Rockville, Md: National Institute of Mental Health; 1976:217-222
30. Fava M, Judge R, Hoog SL, et al. Fluoxetine versus sertraline and paroxetine in major depressive disorder: changes in weight with long-term treatment. J Clin Psychiatry 2000;61:863-867
31. Barr LC, Goodman WK, Price LH. Physical symptoms associated with paroxetine discontinuation [letter]. Am J Psychiatry 1994;151:289
32. Keuthen NJ, Cyr P, Ricciardi JA, et al. Medication withdrawal symptoms in obsessive-compulsive disorder patients treated with paroxetine [letter]. J Clin Psychopharmacol 1994;14:206-207
33. Mallya G, White K, Gunderson C. Is there a serotonergic withdrawal syndrome? [letter] Biol Psychiatry 1993;33:851-852
34. Louie AK, Lannon RA, Ajari LJ. Withdrawal reaction after sertraline discontinuation [letter]. Am J Psychiatry 1994;151:450-451
35. Black DW, Wesner R, Gabel J. The abrupt discontinuation of fluvoxamine in patients with panic disorder. J Clin Psychiatry 1993;54:146-149
36. Zemishlany Z, Aizenberg D, Hermesh H, et al. Withdrawal reactions after clomipramine [in Hebrew]. Harefuah 1992;123:252-255, 307
37. Hollander E, Cohen LJ. The assessment and treatment of refractory anxiety. J Clin Psychiatry 1994;55(2, suppl):27-31